Amyotrophic Lateral Sclerosis News and Research

RSS

Stem cells for the damaged heart

Stem cell research got its latest boost. For the first time, stem cells were injected into the hearts of humans who had suffered serious heart damage, and patients improved dramatically. The scientists found that the stem cells grew into new heart cells to replace the damaged tissue.

5 Dec 2011

Study highlights importance of diagnosing 'overlap syndrome' in sufferers of ALS, FTD

In order to better counsel patients, it is key for clinicians of different disciplines to be aware of, and diagnose, the 'overlap syndrome' between two medical disorders - ALS and FTD - since it significantly affects patient survival. In her new study, Catherine Lomen-Hoerth, from the University of California San Francisco in the US, also highlights that from a research perspective, identifying the syndrome early is an opportunity to study damaged nerve cells and understand more about the early stages of both ALS and FTD.

30 Nov 2011

Neuralstem initiates spinal cord neural stem cell trial in ALS

Neuralstem, Inc. announced that the first patient to receive stem cells in the cervical (upper back) region of the spine was treated on Friday in its ongoing trial to test the safety of its spinal cord neural stem cells in amyotrophic lateral sclerosis.

23 Nov 2011

UCF researchers use stem cells to create nerve-muscle junctions

University of Central Florida researchers, for the first time, have used stem cells to grow neuromuscular junctions between human muscle cells and human spinal cord cells, the key connectors used by the brain to communicate and control muscles in the body.

23 Nov 2011

Scientists discover second faulty gene linked to ALS

Following a major Northwestern Medicine breakthrough that identified a common converging point for all forms of amyotrophic lateral sclerosis (ALS and Lou Gehrig's disease), a new finding from the same scientists further broadens the understanding of why cells in the brain and spinal cord degenerate in the fatal disease.

21 Nov 2011

Nature Medicine publishes dexpramipexole Phase 2 ALS study results

Knopp Biosciences LLC today announced the publication in Nature Medicine of comprehensive results from the Phase 2 study of dexpramipexole, a small-molecule modulator of mitochondrial bioenergetics, in people with amyotrophic lateral sclerosis.

21 Nov 2011

Promising results from dexpramipexole phase 2 trial on ALS

Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.

20 Nov 2011

Researchers discover human genes that might contribute to ALS

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, is a universally fatal neurodegenerative disease. Mutations in two related proteins, TDP-43 and FUS, cause some forms of ALS. Specifically, these two proteins are RNA-binding proteins that connect to RNA to regulate the translation of proteins and other cellular functions such as RNA splicing and editing. In a new study, researchers at the Perelman School of Medicine at the University of Pennsylvania discovered additional human genes with properties similar to TDP-43 and FUS that might also contribute to ALS.

16 Nov 2011

Two proteins conspire to promote amyotrophic lateral sclerosis

Two proteins conspire to promote a lethal neurological disease, according to a study published online this week in the Journal of Experimental Medicine.

15 Nov 2011

Damaged mitochondria equivalent to an environmental disaster in the cell

Current thinking about Parkinson's disease is that it's a disorder of mitochondria, the energy-producing organelles inside cells, causing neurons in the brain's substantia nigra to die or become impaired.

11 Nov 2011

New cellular targets for devastating neurological disorder

In a paper published in the November 9 issue of The Journal of Neuroscience, researchers at the University of California, San Diego School of Medicine and University of Washington describe in deeper detail the pathology of a devastating neurological disorder, but also reveal new cellular targets for possibly slowing its development.

10 Nov 2011

Stem cell therapy for Parkinson’s

U.S. researchers have finally found a way to overcome difficulties in coaxing human embryonic stem cells to become the neurons killed by Parkinson's disease.

8 Nov 2011

Scientists identify mechanism by which GBM promotes neurodegeneration

Researchers from Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have discovered a mechanism by which glioblastoma multiforme (GBM), the most common form of brain cancer, promotes the loss of function or death of neurons, a process known as neurodegeneration.

4 Nov 2011

FDA approves intraspinal injections in spinal cord stem cell ALS trial

Neuralstem, Inc. updated the progress of its ongoing Phase I safety trial of the company's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

24 Oct 2011

Planned clinical trial of Adeona's zinc-based therapy for ALS patients to be featured at ALS Summit

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit on Saturday, October 1, 2011.

1 Oct 2011

FDA approves NeuRx Diaphragm Pacing System to treat ALS

An electronic system that stimulates the nerve of the diaphragm muscles has received approval from the Food and Drug Administration (FDA) for use in patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.

30 Sep 2011

Cedars-Sinai to co-sponsor World Stem Cell Summit

Six leaders in stem cell research from the Cedars-Sinai Regenerative Medicine Institute will be key presenters at the world's largest interdisciplinary stem cell meeting Oct. 3-5 in Pasadena, Calif.

30 Sep 2011

Communication breakdown between nerves and muscles in SMA mouse model

Researchers at the University of Missouri have identified a communication breakdown between nerves and muscles in mice that may provide new insight into the debilitating and fatal human disease known as spinal muscular atrophy.

27 Sep 2011

Families help identify new gene for motor neuron disease

Families suffering from a history of motor neuron disease have helped an international scientific team locate a new gene linked to the incurable disease.

22 Sep 2011

Researchers identify common genetic mutation for ALS, frontotemporal dementia

Frontotemporal dementia and amyotrophic lateral sclerosis, also known as Lou Gehrig's disease -- two fatal neurodegenerative disease with distinct but sometimes overlapping symptoms -- are triggered by a common mutation in many cases, according to researchers who say they have identified the mutated gene.

22 Sep 2011